The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plusCisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed deathprotein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab orPembrolizumab, where approved under local regulations) as first line of treatment forparticipants with human epidermal growth factor receptor 2 (HER2)-positive biliary tractcancer.
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plusCisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed deathprotein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab orPembrolizumab, where approved under local regulations) as first line of treatment forparticipants with human epidermal growth factor receptor 2 (HER2)-positive biliary tractcancer.
